Summary

Other Scenarios:

Buyer: Medicis Pharmaceutical Corporation (MRX) Last Price: 31.02 Market Cap.: 1.73B
Target: Myriad Genetics, Inc. (MYGN) Last Price: 38.94 Market Cap.: 1.68B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 925
Biopharmaceuticals 370
Healthcare Services   154
Medical Devices 261

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 16)
  • Plexion/Plexion TS/Plexion SCT (Sodium Sulfacetamide/Sulfur)
  • Dynacin (Minocycline Hydrochloride)
  • Solodyn Extended Release Tablet (Minocycline HCl)
  • Ziana Gel (Clindamycin/Tretinoin)
Target (Total: 10)
  • MPC-0920 (Direct Thrombin Inhibitor)
  • MPI-49839 (Viral Maturation Inhibitor)
  • Flurizan (R-Flurbiprofen)
  • MPC-2130
Buyer
  • Restylane (Hyaluronic Acid)
  • Perlane (Hyaluronic Acid)
Target
  • Myriad Genetic Laboratories
  • BRACAnalysis/BRACAnalysis Rearrangement Test
  • COLARIS AP
  • COLARIS

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 4)
  • sanofi-aventis (ADR) (SNY)
  • Patheon, Inc. (PTI:CA)
  • Q-Med, Inc. (QMED)
  • Contract Pharmaceuticals Limited
Target (Total: 2)
  • EpiCept Corporation (EPCT)
  • Genetic Technologies Limited (ADR) (GENE)
Buyer (Total: 4)
  • McKesson Corporation (MCK)
  • Cardinal Health, Inc. (CAH)
  • BioMarin Pharmaceutical Inc. (BMRN)
  • Taro Pharmaceutical Industries Ltd. (TAROF)
Target (Total: 0)

n/a

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 391 722
Revenue Per Employee 978,208.3 228,236.4
Total Revenue 95.1 41.0
Total Expenses 86.2 50.1
Other Revenue 0.0 0.0
Cost of Revenue 10.5 7.6
SG&A Expense 62.3 19.1
Research & Development 8.0 23.4
Other Operating Expense 0.0 0.0
Operating Income 8.9 -9.1
Unusual Income 0.0 0.0
LT Debt to Capital 45.94 0
Fwd P/E 26.47 -47.05
Fwd P/Rev 3.79 11.10
Book Value 533.1 339.2
Curr Portion of LTD/Cap Lease 0.0 0.0

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals > Dermatology

Target

Focused (): *Healthcare > Biopharmaceuticals

Business Description

Buyer

Medicis Pharmaceutical Corporation (Medicis) is an independent specialty pharmaceutical company focused primarily on helping patients attain a healthy and youthful appearance and self-image through the development and marketing in the United States of products for the treatment of dermatological, aesthetic and podiatric conditions. It also markets products in Canada for the treatment of dermatological and aesthetic conditions. It offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles, acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, skin and skin-structure infections, seborrheic dermatitis and cosmesis (improvement in the texture and appearance of skin). It offers 17 branded products, including OMNICEF (cefdinir), RESTYLANE (hyaluronic acid), SOLODYN (minocycline HCl, USP), TRIAZ (benzoyl peroxide), VANOS (fluocinonide) Cream 0.1%, and ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel.

Target

Myriad Genetics, Inc. is a biotechnology company focused on the development and marketing of novel therapeutic and molecular diagnostic products. The Company's molecular diagnostic business encompasses efforts in both predictive medicine and personalized medicine. Predictive medicine analyzes genes and their mutations to assess an individual's risk for developing disease later in life. Personalized medicine analyzes genes and their mutations to assess a patient's risk of disease progression, disease recurrence, and drug response and toxicity. As of June 30, 2006, Myriad Genetics, Inc. launched four commercial predictive medicine products, including BRACAnalysis risk assessment for breast and ovarian cancer; COLARIS risk assessment for colon and uterine cancer; COLARIS AP risk assessment for the polyp-forming syndrome of colon cancer, and MELARIS risk assessment for melanoma.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 89.15 78.23
Operating Margin % -9.91 -34.41
Quick Ratio 6.77 14.46
Current Ratio 7.53 14.58
Coverage Ratio -0.61 -0.22
Total Assets 1,084.0 362.1
Return on Equity % 4.12 -11.37
Return on Assets % 2.03 -10.65
Cash+ ST Inv. Per Share 8.99 7.33
Total Debt 453.1 0.0
Total Debt to Equity % 84.98 0
Total Debt to Tangible Equity % 148.43 0
Debt to Asset % 41.79 0.00

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
  
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
  
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
  
Healthcare Services  
Patient Care
The Patient Care Subsector is comprised of companies that provide services to patients for the diagnosis, treatment, and/or prevention of diseases and injuries.
  
Medical Devices
Clinical Diagnostics
The Clinical Diagnostics Subsector includes medical devices that analyze human body specimens within a medical setting. These devices, including equipment, biological and chemical reagents are primarily used for the diagnosis of diseases.
  
Plastic/Reconstructive Surgery
The Plastic/Reconstructive Surgery Subsector includes medical devices that treat and modify a patient's external appearance.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Cardiovascular System  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Target Products:

  • MPC-0920 (Direct Thrombin Inhibitor)
  
Dermatology  
Acne  
Rosacea  
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat chronic inflammatory disorder of the face characterized by redness and pimple formation by inhibiting bacterial folic acid synthesis.

Buyer Products:

  • Plexion/Plexion TS/Plexion SCT (Sodium Sulfacetamide/Sulfur)
  
Vulgaris  
Antibacterial Agents  
Tetracyclines
Therapeutics that treat acne caused by bacterial infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.

Buyer Products:

  • Dynacin (Minocycline Hydrochloride)
  • Solodyn Extended Release Tablet (Minocycline HCl)
  
Antibacterial Agents/Retinoids
Therapeutics that treat acne by preventing bacterial growth and helping in cell differentiation.

Buyer Products:

  • Ziana Gel (Clindamycin/Tretinoin)
  
Keratolytic Agents
Therapeutics that soften, separate, and cause the shedding of skin.

Buyer Products:

  • Triaz (Benzoyl Peroxide)
  
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat bacterial infections of the skin by inhibiting a bacterial enzyme responsible for synthesis of folic acid.

Buyer Products:

  • Plexion/Plexion TS/Plexion SCT (Sodium Sulfacetamide/Sulfur)
  
Aging Disorders  
Wrinkles  
Acetylcholine Inhibitors
Therapeutics that treat wrinkling through prevention of muscle contractions that can result in the formation of facial lines.

Buyer Products:

  • Reloxin (Botulinum Toxin Type A)
  
Lesion/Scaling Disorders  
Dermatitis  
Atopic (Eczema)  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat atopic dermatoses by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Buyer Products:

  • Synalar (Fluocinolone Acetonide)
  
Seborrheic (Dandruff)  
Antifungal Agents  
Imidazoles
Therapeutics that treat and prevent skin diseases caused by fungi.

Buyer Products:

  • Loprox (Ciclopirox)
  
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat bacterial infections of the skin by inhibiting a bacterial enzyme responsible for synthesis of folic acid.

Buyer Products:

  • Plexion/Plexion TS/Plexion SCT (Sodium Sulfacetamide/Sulfur)
  
Dermatoses  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Buyer Products:

  • Lidex (Fluocinonide)
  • Vanos (Fluocinonide)
  
Pruritus  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Buyer Products:

  • Vanos (Fluocinonide)
  
Psoriasis  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Buyer Products:

  • Synalar (Fluocinolone Acetonide)
  
Pigmentation Disorders  
Hyperpigmentation  
Enzymatic Oxidation Inhibitors
Therapeutics that treat disorders characterized by darkening of the skin by inhibiting metabolic processes of pigment producing skin cells.

Buyer Products:

  • Esoterica (Hydroquinone)
  
Endocrinology/Metabolism  
Intermediary Metabolism Disorders  
Urea Cycle Disorders  
Glutamine Acetylyzing Agents
Therapeutics that conjugate with glutamine to help excrete nitrogen waste.

Buyer Products:

  • Buphenyl (Sodium Phenylbutyrate)
  • Ammonul (Sodium Phenylacetate, Sodium Benzoate)
  
Immunology
Autoimmune Disorders  
Psoriasis  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat a chronic autoimmune disease characterized by softening, separating, causing the shedding of the horny layer of the skin with a steroidal compound.

Buyer Products:

  • Synalar (Fluocinolone Acetonide)
  • Vanos (Fluocinonide)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.

Target Products:

  • MPI-49839 (Viral Maturation Inhibitor)
  
Infectious Diseases
Bacterial  
Antibacterial Agents  
Broad Spectrum  
Antibiotics  
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.

Buyer Products:

  • Omnicef (Cefdinir)
  
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.

Buyer Products:

  • Dynacin (Minocycline Hydrochloride)
  
Mycological (Fungal)  
Antifungal Agents  
Narrow Spectrum  
Dermatology  
Tinea Corporis (Ringworm)  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Loprox (Ciclopirox)
  
Tinea Cruris (Jock Itch)  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the groin and perineum by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Loprox (Ciclopirox)
  
Tinea Pedis  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the feet by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Loprox (Ciclopirox)
  
Tinea Versicolor  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of skin exposed to the sun characterized by patches of depigmentation by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Loprox (Ciclopirox)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.

Target Products:

  • MPI-49839 (Viral Maturation Inhibitor)
  
Neurology  
Neurological Disorders  
Alzheimer`s Disease  
Gamma Secretase Inhibitors
Therapeutics that treat Alzheimer's Disease by selectively lowering levels of Amyloid beta 42, a toxic peptide to neural cells.

Target Products:

  • Flurizan (R-Flurbiprofen)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.

Target Products:

  • Flurizan (R-Flurbiprofen)
  
Oncology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Target Products:

  • MPC-2130
  • Azixa/Formely MPC-6827 (Tubulin Inhibitor)
  
Healthcare Services  
Patient Care  
Ambulatory/Outpatient  
Diagnostic  
Laboratory  
Specialized
Specialized laboratory testing services involving highly specialized equipment, personnel, and procedures.

Target Products:

  • Myriad Genetic Laboratories
  
Medical Devices
Clinical Diagnostics  
Chemistry  
Reagents  
Test Kits  
Genetic Analysis  
Cancers  
Breast Cancer
A test designed to determine pre-disposition to breast cancer.

Target Products:

  • BRACAnalysis/BRACAnalysis Rearrangement Test
  
Colorectal Cancer (Colon Cancer)
A test designed to determine pre-disposition to colorectal cancer.

Target Products:

  • COLARIS AP
  • COLARIS
  
Melanoma (Skin Cancer)
Test designed to determine pre-disposition to melanoma.

Target Products:

  • MELARIS
  
Ovarian Cancer
Test designed to determine pre-disposition to ovarian cancer.

Target Products:

  • BRACAnalysis/BRACAnalysis Rearrangement Test
  
Pancreatic Cancer
Test designed to determine pre-disposition to pancreatic cancer.

Target Products:

  • MELARIS
  
Plastic/Reconstructive Surgery  
Treatment  
Wrinkle Removal  
Hyaluronic Acid  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Johnson & Johnson n/a 178,978.324 16.91 15.32 3.13 2.97 n/a
sanofi-aventis (ADR) n/a 117,047.304 21.40 11.89 2.91 2.99 n/a
Bristol Myers Squibb Co. n/a 62,072.775 39.76 22.41 3.50 3.22 16.98
Allergan, Inc. n/a 18,441.814 51.06 27.11 5.55 4.89 300.36
Shire plc (ADR) n/a 13,939.161 42.27 36.90 7.28 6.15 7.17
Cytyc Corporation n/a 5,029.764 85.30 32.96 7.90 6.75 n/a
Warner Chilcott Ltd. n/a 4,888.547 n/a 20.11 6.06 5.61 n/a
Biovail Corporation (USA) n/a 3,215.987 13.57 13.73 2.94 4.74 5.76
Valeant Pharmaceuticals International n/a 1,600.204 n/a 23.26 1.74 1.72 n/a
Sciele Pharma Inc. n/a 828.305 16.86 14.60 2.68 2.28 7.88
Obagi Medical Products, Inc. n/a 370.851 49.14 24.56 4.42 3.69 36.13
Bradley Pharmaceuticals, Inc. n/a 346.406 28.90 30.29 2.34 2.28 175.31
XOMA Limited n/a 346.346 n/a -9.03 9.58 6.58 n/a
CollaGenex Pharmaceutical, Inc n/a 266.671 n/a -14.79 7.22 4.24 4.65
Taro Pharmaceutical Industries Ltd. n/a 262.481 46.23 21.82 0.88 0.85 1.11
Barrier Therapeutics, Inc. n/a 200.296 n/a -3.78 22.29 7.54 5.43
Artes Medical, Inc. n/a 124.635 n/a -5.54 86.46 9.15 3.30
DFB Pharmaceuticals, Inc. n/a n/a n/a n/a n/a n/a n/a
Nestle S.A. n/a n/a n/a 17.80 n/a n/a n/a
Groupe L'Oreal n/a n/a n/a n/a n/a n/a n/a
Target
  ChoicePoint Inc. n/a 3,262.336 189.27 23.85 3.07 3.02 n/a
Verenium Corporation n/a 331.601 n/a -10.86 6.50 5.89 9.50
EPIX Pharmaceuticals, Inc. n/a 174.085 n/a -2.86 27.67 8.77 n/a
Orchid Cellmark, Inc. n/a 151.165 n/a -51.80 2.59 2.50 4.00
Healthcare Technologies, Ltd n/a 7.934 n/a n/a 0.56 n/a n/a

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  sanofi-aventis (ADR) n/a 117,047.304 21.40 11.89 2.91 2.99 n/a
Patheon, Inc. n/a 381.131 n/a n/a 0.53 n/a 1.80
Q-Med, Inc. n/a 59.832 n/a -5.22 2.91 1.60 6.17
Contract Pharmaceuticals Limited n/a n/a n/a n/a n/a n/a n/a
Target
  EpiCept Corporation n/a 69.669 n/a n/a 35.55 n/a n/a
Genetic Technologies Limited (ADR) n/a 44.816 n/a n/a 6.10 n/a 4.79

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  McKesson Corporation 56.80% 17,326.903 18.98 18.26 0.19 0.18 5.53
Cardinal Health, Inc. 19.30% 26,290.725 19.48 20.66 0.30 0.31 7.59
BioMarin Pharmaceutical Inc. n/a 1,744.552 n/a -84.05 18.71 14.83 13.13
Taro Pharmaceutical Industries Ltd. n/a 262.481 46.23 21.82 0.88 0.85 1.11

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Abbott Laboratories n/a 81,438.826 42.29 19.04 3.38 3.58 n/a
Buyer
  sanofi-aventis (ADR) n/a 117,047.304 21.40 11.89 2.91 2.99 n/a
Abbott Laboratories n/a 81,438.826 42.29 19.04 3.38 3.58 n/a
Cardinal Health, Inc. n/a 26,290.725 19.48 20.66 0.30 0.31 7.59
McKesson Corporation n/a 17,326.903 18.98 18.26 0.19 0.18 5.53
BioMarin Pharmaceutical Inc. n/a 1,744.552 n/a -84.05 18.71 14.83 13.13
Patheon, Inc. n/a 381.131 n/a n/a 0.53 n/a 1.80
Taro Pharmaceutical Industries Ltd. n/a 262.481 46.23 21.82 0.88 0.85 1.11
Q-Med, Inc. n/a 59.832 n/a -5.22 2.91 1.60 6.17
Ipsen S.A. n/a n/a n/a n/a n/a n/a n/a
AAIPharma Inc. n/a n/a n/a n/a n/a n/a n/a
Contract Pharmaceuticals Limited n/a n/a n/a n/a n/a n/a n/a
Dow Pharmaceutical Sciences, Inc. n/a n/a n/a n/a n/a n/a n/a
Astellas Pharma Inc. n/a n/a n/a n/a n/a n/a n/a
Target
  Abbott Laboratories n/a 81,438.826 42.29 19.04 3.38 3.58 n/a
EpiCept Corporation n/a 69.669 n/a n/a 35.55 n/a n/a
Genetic Technologies Limited (ADR) n/a 44.816 n/a n/a 6.10 n/a 4.79
University of Utah n/a n/a n/a n/a n/a n/a n/a
Mayo Foundation for Medical Education and Research n/a n/a n/a n/a n/a n/a n/a
Government - United States n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 369.2 143.7 512.9
Other Revenue 0.0 0.0 0.0
Total Revenue 369.2 143.7 512.9
Cost of Revenue 40.1 31.3 71.3
SG&A Expense 217.9 63.0 280.9
Depreciation & Amortization 22.6 0.0 22.6
Research & Development 72.6 98.8 171.5
Interest Expense 0.0 0.0 0.0
Other Operating Expense 0.0 0.0 0.0
Unusual Expense (Income) 52.6 0.0 52.6
Total Expenses 405.8 193.1 598.9
Operating Income -36.6 -49.4 -86.0
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 22.1 10.8 33.0
Other, Net 0.0 0.0 0.0
Income Before Taxes -14.4 -38.6 -53.0
Income Taxes -36.4 0.0 -36.4
Income After Taxes 22.0 -38.6 -16.6
Net Income - Excl. Xord. Items 22.0 -38.6 -16.6
Net Income - Incl. Xord. Items 22.0 -38.6 -16.6
Income Avail. to Common 22.0 -38.6 -16.6
Share Items
Basic Avg. Shares Outstanding 55.6 41.5 97.1
Basic EPS - Excl. Xord. Items 0.40 n/a -0.17
Basic EPS - Incl. Xord. Items 0.40 n/a -0.17
Full Dilution Adjustment 1.7 0.0 1.7
Fully Diluted Shares Outstanding 71.7 41.5 113.2
F.D. EPS - Excl. Xord. Items 0.31 n/a -0.15
F.D. EPS - Incl. Xord. Items 0.31 n/a -0.15
Dividends Per Common Share 0.12 0.00 0.12
Balance Sheet
Assets
Cash and Equivalents 83.9 194.9 278.8
ST Investments 560.6 109.5 670.0
Accounts Receivable 18.0 27.6 45.6
Inventory 30.8 0.0 30.8
Prepayments and Advances 0.0 2.8 2.8
Other Current Assets 43.7 0.0 43.7
Current Assets 737.0 334.7 1,071.7
PPE 0.0 62.3 62.3
Accum D&A 0.0 -39.0 -39.0
PPE, Net 7.5 23.4 30.8
Goodwill & Intangibles 227.9 0.0 227.9
Other Assets 0.0 0.0 0.0
Other LT Assets 111.7 4.1 115.7
Total Assets 1,084.0 362.1 1,446.2
Liabilities
Accounts Payable 51.4 11.0 62.4
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 0.0 11.6 11.6
ST Debt 0.0 0.0 0.0
Other (Current) Liabilities 46.5 0.4 46.9
Current Liab. 97.9 23.0 120.8
LT Debt 453.1 0.0 453.1
Total LT Debt 453.1 0.0 453.1
Other LT Liab. 0.0 0.0 0.0
Total Liabilities 550.9 23.0 573.9
Shareholders Equity
Common Stock 1.0 0.4 1.4
Additional Paid in Capital 615.2 583.5 1,198.7
Retained Earnings 259.2 -244.6 14.6
Treasure Stock -342.9 0.0 -342.9
Other Equity 0.7 -0.1 0.6
Total Equity 533.1 339.2 872.3
Total Liab. & Equity 1,084.0 362.1 1,446.2
Shares Outstanding 55.8 43.0 98.9
Cash Flow
Operating Cash Flow
CF Net Income 22.0 -38.6 -16.6
CF Depreciation 22.6 7.3 30.0
CF Deferred Taxes -57.1 0.0 -57.1
Other Non-Cash Items 91.2 10.5 101.7
Change in Working Capital 17.5 -8.7 8.9
Total Cash From Operating Activities 96.3 -29.4 66.9
Investing Cash Flow (not calculated)
Capital Expenditures -8.0 -10.5 -18.5
Other Investing Cash Flows -274.3 14.1 -260.2
Total Cash From Investing Activities -282.2 3.6 -278.7
Financing Cash Flow (not calculated)
Dividends Paid -6.6 0.0 -6.6
Purchase Or Sale of Stock 27.7 114.3 142.0
Purchase and Retirement of Debt 0.0 0.0 0.0
Other Financing Cash Flow 3.0 0.0 3.0
Total Cash From Financing Activities 24.1 114.3 138.4
Exchange Rate Effects -0.1 0.0 -0.1
Net Change in Cash -161.9 88.5 -73.4
Cash Taxes Paid 35.7 0.0 35.7